TransDigm Enters Acquisition Agreement with Semco

TransDigm Group Incorporated (NYSE: TDG), announced today that it has entered into a definitive agreement to acquire the stock of Semco Instruments Inc. (Semco), for approximately $73.5 million in cash.

The acquisition, which is subject to certain conditions, is expected to close during the fourth quarter of fiscal 2010.  Semco, located in Valencia, California and in Nogales, Mexico, manufactures proprietary, highly engineered components for all major turbo-prop, turbo-fan, and turbo-shaft engine manufacturers. Semco had annual revenues for calendar year 2009 of approximately $38 million, with significant aftermarket content.

Semco designs and manufactures highly engineered sensors, thermocouples and other products. Significant platform applications include ERJ 170/190, ATR 42/72, Dash-8, the Cessna, Lear and Raytheon family of business jets, as well as a broad range of commercial and military helicopters. Major customers include Pratt Whitney, Hamilton Sundstrand, Sikorsky, Honeywell, General Electric, and the US Government.

W. Nicholas Howley, Chairman and CEO of TransDigm Group Incorporated stated, "Semco is an outstanding business that both fits well with our strategy and also allows us to expand our content for certain engine applications.  The company has a significant installed base of product and continues to benefit by its strong relationships and OEM production positions with the industry's premier engine manufacturers.  Its diversified market presence provides stability to cash flows and should provide significant future value creation opportunities."

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.